Wall Street brokerages forecast that Nurix Therapeutics, Inc. (NASDAQ:NRIX) will announce $7.35 million in sales for the current quarter, according to Zacks. Three analysts have provided estimates for Nurix Therapeutics’ earnings, with the lowest sales estimate coming in at $6.50 million and the highest estimate coming in at $8.20 million. The business is scheduled to announce its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that Nurix Therapeutics will report full year sales of $32.07 million for the current fiscal year, with estimates ranging from $29.75 million to $34.50 million. For the next financial year, analysts anticipate that the company will post sales of $45.47 million, with estimates ranging from $42.00 million to $52.40 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Nurix Therapeutics.
NRIX has been the topic of several analyst reports. JPMorgan Chase & Co. initiated coverage on Nurix Therapeutics in a report on Tuesday, August 18th. They set an “overweight” rating and a $35.00 price objective on the stock. Stifel Nicolaus assumed coverage on shares of Nurix Therapeutics in a research report on Tuesday, August 18th. They issued a “buy” rating and a $34.00 target price on the stock. Piper Sandler assumed coverage on shares of Nurix Therapeutics in a research report on Tuesday, August 18th. They issued an “overweight” rating and a $40.00 target price on the stock. Finally, Needham & Company LLC assumed coverage on shares of Nurix Therapeutics in a research report on Tuesday, August 18th. They issued a “buy” rating and a $35.00 target price on the stock.
Shares of NRIX opened at $25.48 on Friday. Nurix Therapeutics has a fifty-two week low of $15.21 and a fifty-two week high of $30.00.
About Nurix Therapeutics
Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's lead product candidates in preclinical stage include NX-2127, an orally available Bruton's tyrosine kinase degrader for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications.
Recommended Story: Certificate of Deposit (CD) For Risk Adverse Investors?
Get a free copy of the Zacks research report on Nurix Therapeutics (NRIX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.